What is the price-to-earnings ratio of Medicamen Biotech?
The price-earnings ratio of Medicamen Biotech is currently 4.04.
Medicamen Biotech's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Comparing Medicamen Biotech's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
The P/S ratio is instrumental for investors evaluating Medicamen Biotech's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Variations in Medicamen Biotech’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
The price-earnings ratio of Medicamen Biotech is currently 4.04.
The price-to-earnings ratio of Medicamen Biotech has increased by -33.77% fallen (meaning "decreased" or "dropped") compared to last year.
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Yes, the price-to-earnings ratio of Medicamen Biotech is high compared to other companies.
An increase in the price-earnings ratio of Medicamen Biotech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
A decrease in the price-earnings ratio of Medicamen Biotech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
Some factors that influence the price-earnings ratio of Medicamen Biotech are the company's growth, financial position, industry development, and the overall economic situation.
Over the past 12 months, Medicamen Biotech paid a dividend of 1 INR . This corresponds to a dividend yield of about 0.2 %. For the coming 12 months, Medicamen Biotech is expected to pay a dividend of 1 INR.
The current dividend yield of Medicamen Biotech is 0.2 %.
Medicamen Biotech pays a quarterly dividend. This is distributed in the months of .
Medicamen Biotech paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 1 INR are expected. This corresponds to a dividend yield of 0.2 %.
Medicamen Biotech is assigned to the 'Health' sector.
To receive the latest dividend of Medicamen Biotech from 10/27/2023 amounting to 1 INR, you needed to have the stock in your portfolio before the ex-date on 9/20/2023.
The last dividend was paid out on 10/27/2023.
In the year 2023, Medicamen Biotech distributed 1 INR as dividends.
The dividends of Medicamen Biotech are distributed in INR.
Our stock analysis for Medicamen Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medicamen Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.